Growth hormone therapy in health and disease: could GH and IGF-I combination therapy combat the somatopause?

Michael Graham, Peter Evans, Bruce Davies, Non Thomas, Julien Baker

Research output: Contribution to journalArticle

Abstract

Recombinant human growth hormone (rhGH) has allowed investigations of the role of GH and identified the effects of rhGH replacement in GH-deficiency (GHD). Both obese and elderly subjects with low insulin like-growth factor-I (IGF-I) levels have functional GHD. Administration of rhGH to elderly subjects with low IGF-I levels results in reversal of changes associated with GHD. These changes are similar to those shown in adults with GHD with rhGH replacement. RhGH replacement in the elderly and obese has been compromised by side effects, due to hypersensitivity. Doses are required to be titrated to individual needs. Insulin like growth factor-I (IGF-I) mediates some of the metabolic actions of GH and has both GH-like and insulin-like actions. Both GH and IGF-I have a net anabolic effect enhancing whole body protein synthesis improving anthropometry in GHD. Both hormones have been used in catabolism and have been effective in counteracting the protein wasting effects of medicines such as glucocorticoids. IGF-I may be an appropriate combination agent to use in conditions where carbohydrate metabolism is impaired. The pendulum of research has progressed towards IGF-I and it may be possible that the two can be used together to treat the sarcopenic effects of the somatopause, with an application for use in obesity?
Original languageEnglish
Pages (from-to)1-24
Number of pages24
JournalJournal of Exercise Physiology Online
Volume12
Issue number6
Publication statusPublished - 1 Dec 2009

Fingerprint

Insulin-Like Growth Factor I
Growth Hormone
Human Growth Hormone
Health
Therapeutics
Anabolic Agents
Anthropometry
Carbohydrate Metabolism
Glucocorticoids
Hypersensitivity
Proteins
Obesity
Hormones
Insulin
Research

Keywords

  • anthropometry
  • exercise
  • peptide hormones
  • performance

Cite this

@article{227e3f4788aa4bea9b092c2d10e19d5b,
title = "Growth hormone therapy in health and disease: could GH and IGF-I combination therapy combat the somatopause?",
abstract = "Recombinant human growth hormone (rhGH) has allowed investigations of the role of GH and identified the effects of rhGH replacement in GH-deficiency (GHD). Both obese and elderly subjects with low insulin like-growth factor-I (IGF-I) levels have functional GHD. Administration of rhGH to elderly subjects with low IGF-I levels results in reversal of changes associated with GHD. These changes are similar to those shown in adults with GHD with rhGH replacement. RhGH replacement in the elderly and obese has been compromised by side effects, due to hypersensitivity. Doses are required to be titrated to individual needs. Insulin like growth factor-I (IGF-I) mediates some of the metabolic actions of GH and has both GH-like and insulin-like actions. Both GH and IGF-I have a net anabolic effect enhancing whole body protein synthesis improving anthropometry in GHD. Both hormones have been used in catabolism and have been effective in counteracting the protein wasting effects of medicines such as glucocorticoids. IGF-I may be an appropriate combination agent to use in conditions where carbohydrate metabolism is impaired. The pendulum of research has progressed towards IGF-I and it may be possible that the two can be used together to treat the sarcopenic effects of the somatopause, with an application for use in obesity?",
keywords = "anthropometry, exercise, peptide hormones, performance",
author = "Michael Graham and Peter Evans and Bruce Davies and Non Thomas and Julien Baker",
year = "2009",
month = "12",
day = "1",
language = "English",
volume = "12",
pages = "1--24",
journal = "Journal of Exercise Physiology Online",
issn = "1097-9751",
publisher = "American Society of Exercise Physiologists",
number = "6",

}

Growth hormone therapy in health and disease : could GH and IGF-I combination therapy combat the somatopause? / Graham, Michael; Evans, Peter; Davies, Bruce; Thomas, Non; Baker, Julien.

In: Journal of Exercise Physiology Online, Vol. 12, No. 6, 01.12.2009, p. 1-24.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Growth hormone therapy in health and disease

T2 - could GH and IGF-I combination therapy combat the somatopause?

AU - Graham, Michael

AU - Evans, Peter

AU - Davies, Bruce

AU - Thomas, Non

AU - Baker, Julien

PY - 2009/12/1

Y1 - 2009/12/1

N2 - Recombinant human growth hormone (rhGH) has allowed investigations of the role of GH and identified the effects of rhGH replacement in GH-deficiency (GHD). Both obese and elderly subjects with low insulin like-growth factor-I (IGF-I) levels have functional GHD. Administration of rhGH to elderly subjects with low IGF-I levels results in reversal of changes associated with GHD. These changes are similar to those shown in adults with GHD with rhGH replacement. RhGH replacement in the elderly and obese has been compromised by side effects, due to hypersensitivity. Doses are required to be titrated to individual needs. Insulin like growth factor-I (IGF-I) mediates some of the metabolic actions of GH and has both GH-like and insulin-like actions. Both GH and IGF-I have a net anabolic effect enhancing whole body protein synthesis improving anthropometry in GHD. Both hormones have been used in catabolism and have been effective in counteracting the protein wasting effects of medicines such as glucocorticoids. IGF-I may be an appropriate combination agent to use in conditions where carbohydrate metabolism is impaired. The pendulum of research has progressed towards IGF-I and it may be possible that the two can be used together to treat the sarcopenic effects of the somatopause, with an application for use in obesity?

AB - Recombinant human growth hormone (rhGH) has allowed investigations of the role of GH and identified the effects of rhGH replacement in GH-deficiency (GHD). Both obese and elderly subjects with low insulin like-growth factor-I (IGF-I) levels have functional GHD. Administration of rhGH to elderly subjects with low IGF-I levels results in reversal of changes associated with GHD. These changes are similar to those shown in adults with GHD with rhGH replacement. RhGH replacement in the elderly and obese has been compromised by side effects, due to hypersensitivity. Doses are required to be titrated to individual needs. Insulin like growth factor-I (IGF-I) mediates some of the metabolic actions of GH and has both GH-like and insulin-like actions. Both GH and IGF-I have a net anabolic effect enhancing whole body protein synthesis improving anthropometry in GHD. Both hormones have been used in catabolism and have been effective in counteracting the protein wasting effects of medicines such as glucocorticoids. IGF-I may be an appropriate combination agent to use in conditions where carbohydrate metabolism is impaired. The pendulum of research has progressed towards IGF-I and it may be possible that the two can be used together to treat the sarcopenic effects of the somatopause, with an application for use in obesity?

KW - anthropometry

KW - exercise

KW - peptide hormones

KW - performance

M3 - Article

VL - 12

SP - 1

EP - 24

JO - Journal of Exercise Physiology Online

JF - Journal of Exercise Physiology Online

SN - 1097-9751

IS - 6

ER -